Bram de Wilde

13PUBLICATIONS
199CO-AUTHORS
Haematological tumoursCentral nervous systemPredictive and prognostic markersMolecular targetsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Dec 12, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Juliet C Gray, Rebekah Weston, Cormac Owens

|Dec 03, 2024
Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions.

Audrey-Anne Lamoureux, Michael J Fisher, Lauriane Lemelle

|Jan 08, 2024
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial.

Lucas Moreno, Rebekah Weston, Cormac Owens

|Jan 18, 2023
Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma.

Nathalie S M Lak, Lieke M J van Zogchel, Lily Zappeij-Kannegieter

|Aug 10, 2022
The Critical Role of Academic Clinical Trials in Pediatric Cancer Drug Approvals: Design, Conduct, and Fit for Purpose Data for Positive Regulatory Decisions.

Bram De Wilde, Elly Barry, Elizabeth Fox

|Jul 25, 2022
Whole genome sequencing and inheritance-based variant filtering as a tool for unraveling missing heritability in pediatric cancer.

Charlotte Derpoorter, Ruben Van Paemel, Katrien Vandemeulebroecke

Pageof 3